Ultragenyx Pharmaceutical shares surged 12.6% after FDA approval of Fayuvi, its gene therapy for Sanfilippo syndrome Type A, though the RARE stock remains down sharply year-to-date following a failed trial.
Market Samachar is a news aggregator. This article was originally published by Markets-Economic Times. Tap the button above to read the full story on their site.